People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The FDA has approved Spravato (esketamine) nasal spray for use as monotherapy for patients with treatment-resistant depression.

Johnson & Johnson has priced its new Spravato nasal spray for treatment ... has a wholesale acquisition cost of $295 per 28 mg device and costs around $32,400 for a year’s treatment, says ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...

Johnson & Johnson’s Spravato nasal spray has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced ...